Long-Term Data From SEQUOIA Study of Zanubrutinib in CLLByMarc S. Hoffmann, MDDecember 17th 2025Dr. Marc S. Hoffmann reveals promising 6-year results from the SEQUOIA study on zanubrutinib for chronic lymphocytic leukemia at the 2025 ASH Meeting.